leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals completing drawdown of $3.5 million convertible note with US-based investment fund

The drawdown will be provided through the issue of 3.85 million convertible notes with a face value of A$1 each to Mercer Street Global Opportunity Fund LLC.

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals nearing drawdown completion of $3.5 million convertible notes with US Mercer Street Global Opportunity Fund
MGC Pharma creates premium phytocannabinoid-based products from its GMP facility in Europe

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKTS:MGCLF) (FRA:H5O) is completing a drawdown under a convertible securities financing agreement with United States-based investment fund Mercer Street Global Opportunity Fund LLC.

The drawdown will provide the company with funding of A$3.5 million, which has already been approved by shareholders at the Annual General Meeting on November 4.  

This will be provided through the issue of 3.85 million convertible notes with a face value of A$1 each to Mercer Street, with the convertible notes issued through a prospectus.

Australian telehealth platform

MGC Pharma recently acquired Australian telehealth medicinal cannabis clinic Medicinal Cannabis Clinics (MCC), a wholly-owned subsidiary of Cannvalate Pty Ltd.

MCC was established in 2019 and has an extensive doctor and patient network that enables eligible patients to access high-quality and affordable medicinal cannabis products.

Since incorporation, MCC has facilitated more than 4,000 medical consultations with pre-screened eligible patients and has shown continued month-on-month growth.

The clinic utilises video telemedicine, allowing its doctors to prescribe the range of cannabinoid medications available in Australia.

This transaction provides MGC Pharma with turnkey access to over 600 pharmacy accounts and patients can also leverage on existing seamless delivery infrastructure so medication can be dispensed and delivered straight to the patient’s door.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.026 AUD

ASX:MXC
Market: ASX
Market Cap: $46.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharma reports 100% success rate in its phase II ArtemiC study in COVID-19

MGC Pharmaceuticals Ltd’s (ASX:MXC) (OTCMKTS:MGCLF) (FRA:MGC) Roby Zomer speaks to Proactive's Andrew Scott following the publication of results in its phase II double blind clinical trial of ArtemiC in COVID-19 patients. The results show the treatment improved the clinical recovery of all...

on 12/14/2020

2 min read